Viridian Therapeutics is advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Our patient-centric model of innovation leverages proven biology and technology to efficiently craft medicines to meet the needs of patients and healthcare providers.
Viridian’s most advanced program, VRDN-001, is a monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R), and is in development for the treatment of thyroid eye disease (TED). TED is a debilitating auto-immune disease that causes inflammation and fibrosis of the orbital tissues surrounding the eye, leading to proptosis, or bulging of the eyes, redness and swelling, diplopia (double vision), pain, and potential blindness. Current treatments options are limited and burdensome.